Strides Pharma Science Limited has informed the Exchange regarding a press release dated May 18, 2026, titled "Strides Delivers Strong Performance with FY26 EBITDA at ₹9,253m, Operational PAT at ₹5,181m, 50% YoY Growth".
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Strides Pharma reported robust FY26 results with revenue of ₹48,587m (up 6.4% YoY). EBITDA grew 15.3% to ₹9,253m with margin expanding 140bps to 19%. Operational PAT surged 50.3% to ₹5,181m, reflecting strong operating leverage. US market revenue was flat at ₹24,897m (2% growth), while Ex-US markets outperformed with 21% YoY growth reaching ₹22,404m. Net Debt stood at ₹14,365m with Net Debt/EBITDA improving to 1.55x from 1.9x in FY25. RoCE increased to 15.8% from 14.9%. Board recommended dividend of ₹5 per share.
Strong profitability metrics and margin expansion indicate operational efficiency improvements. The 50% PAT growth and improving leverage ratios are positive signals for shareholders, though muted US market growth may limit upside.